Drug intelligence / Profile preview

Spikevax X

Development stage: Unknown
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Spikevax X is an mRNA vaccine developed by Moderna for active immunization against SARS-CoV-2, likely representing a specific, possibly variant-adapted, formulation of the broader Spikevax vaccine. It functions by delivering nucleoside-modified messenger RNA (mRNA) into host cells. This mRNA instructs the cells to produce the SARS-CoV-2 spike (S) antigen, which then elicits an immune response in the vaccinated individual, providing protection against COVID-19. The drug is currently undergoing post-marketing surveillance to evaluate adverse events and other safety information in the South-Korean population, indicating its approved status.

Brand names: Spikevax X

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on Spikevax X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spikevax X.

Explore the full profile